Navigation Links
Oncothyreon announces closing of $11.1 million registered direct financing
Date:5/27/2009

SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of 3,878,993 shares of its common stock and warrants to purchase 2,909,244 shares of its common stock for gross proceeds of approximately $11.1 million on May 26, 2009. Oncothyreon sold the shares and warrants for $2.85 per unit (each unit consisting of one share and a warrant to purchase 0.75 shares of common stock). The exercise price of the warrants is $3.92 per share. The warrants will be exercisable at any time on or after the six-month anniversary and on or prior to the fifth anniversary of the closing of the transaction on May 26, 2009. Oncothyreon plans to use the proceeds from this financing for general corporate purposes. Boenning & Scattergood, Inc. acted as exclusive placement agent in the transaction.

A registration statement relating to these securities (File # 333-149837) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor, shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement, can be obtained at the Securities and Exchange Commission's website, www.sec.gov, from Oncothyreon at its Seattle, Washington address below or Boenning & Scattergood, Inc. by calling 1-800-883-1212.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
2. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
3. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon reports first quarter 2009 financial results
5. Oncothyreon regains compliance with NASDAQ listing requirements
6. Oncothyreon to present at Invest Northwest 2009
7. Oncothyreon reports full year and fourth quarter 2008 financial results
8. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
9. Oncothyreon to present at BIO CEO & Investor Conference 2009
10. Oncothyreon reports third quarter 2008 financial results
11. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... Last ... planning for corporate executives and entrepreneurs, held The Future of San Diego Life Science ... the San Diego life science community attended the event with speakers Dr. Rich Heyman, ...
(Date:5/23/2016)... Oxitec CEO Hadyn Parry ... a.m. ET before the United States House Committee on Science, ... play in controlling the spread of the Aedes aegypti ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec ... gene. Trials in Brazil , ...
(Date:5/20/2016)... ... ... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma ., is proud ... of their own patients with the VetStem Cell Therapy. Each of these veterinarians has ... patients. , The veterinarians are Dr Ross Rich former owner of Cave Creek ...
(Date:5/19/2016)... Columbia , May 19, 2016  AdvancedFlow ... Innovations Inc. (AGI), based out of ... Greenlane Biogas Ltd. to its existing portfolio of ... manufacturing agreement. AFS along with its sister companies ... is a vertically integrated industrial group that specializes ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):